New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

February 2017

Welcome to the February 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the February issue!

The PharmSource Team

 

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type January 2017 YTD 2017
Early Development 131 131
Late Development 122 122
Biologic 128 128
Small Molecule 277 277
Parenteral 137 137
Oral 99 99
New Financings 69 69
Total Drug Leads 373 373
Total Device &
Diagnostic Leads
138 138

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


 

Pipeline Tip

Cellestia Biotech plans to initiate a Phase I study for CB-103, an oral pan-NOTCH inhibitor, as a targeted oncology therapy:

  • Therapeutic Area: Oncology – Other
  • Dosage Form: Oral
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of Cellestia, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
 

Using the PharmSource Lead Sheet Icons to Identify Early Opportunities

by Blythe Moore, Director, Account Management

Icons are everywhere! But don’t ignore the icons at the top of your weekly PharmSource Lead Sheet. These small symbols convey crucial information about drugs and financings being reported weekly in the Lead Sheet.

The I symbol denotes “Plans to initiate next-phase trial.” If your sweet spot is Phase II development and later, don’t ignore Phase I leads. You need to know what drugs are in Phase I to contact companies before the drug has moved into Phase II. The I symbol can save you time by… read on
 

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is a U.S. public bio/pharmaceutical company that focuses on developing transdermal cannabinoid treatments for patients with high unmet medical needs. They raised raised $50.4 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund clinical trials with ZYN001 and ZYN002, including… read on
 
 

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Ivantis, Inc.

Ivantis is a U.S. private company that develops solutions for the treatment of glaucoma. They raised $25 million in a completion of a Series C venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support US approval and commercialization efforts for the Hydrus Microstent… read on
 

Stars Seem Aligned for Healthy CDMO/CMO Market

by Jim Miller, President, PharmSource, A GlobalData company

A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% from their highs in mid-2015, and by mid-February, they were off another 28%. Because CDMOs and CROs get so much of their business from externally-financed companies, the negative energy surrounding emerging bio/pharma did not bode well for the industry.

The valuations and levels of public offering activity in 2014 and 2015 were not sustainable, and the NBI has never gotten back close to the levels it reached in 2015. Nevertheless, fundraising by emerging biopharma companies held its own in 2016. Financing for emerging bio/pharma from venture capital, public equity, and partnering sources was ahead of 2013 levels, and those companies showed… read on
 

How much longer is the boom in the CDMO and CRO business likely to continue?

PharmSource’s just-released trend report, Follow the Money: The Outlook for Outsourced Spending on Early Development Services, examines the link between external funding sources and early drug development, and addresses the following:

1. How close is the link between early development activity and the external funding environment?

2. What happens to R&D spending when an emerging bio/pharma company gets financing? What happens to other spending categories?

3. What is the cost of getting a candidate into Phase 1 and Phase 2?


 

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / 1-703-383-4903, ext. 112 (ET USA).